Abstract
Recent asthma exacerbation history independently predicts future exacerbation risk. Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component of IL-4/IL-13, key and central drivers of type 2 inflammation. In VOYAGE (NCT02948959), dupilumab significantly reduced asthma exacerbation rates (AER) and improved lung function vs placebo in 6–11 year-old children with uncontrolled, moderate-to-severe asthma. Safety was consistent with the dupilumab safety profile. This post hoc analysis assessed the impact of exacerbation history on dupilumab efficacy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
